BR112023004874A2 - Construções de ácido nucléico, vetores virais e partículas virais - Google Patents

Construções de ácido nucléico, vetores virais e partículas virais

Info

Publication number
BR112023004874A2
BR112023004874A2 BR112023004874A BR112023004874A BR112023004874A2 BR 112023004874 A2 BR112023004874 A2 BR 112023004874A2 BR 112023004874 A BR112023004874 A BR 112023004874A BR 112023004874 A BR112023004874 A BR 112023004874A BR 112023004874 A2 BR112023004874 A2 BR 112023004874A2
Authority
BR
Brazil
Prior art keywords
viral
nucleic acid
viral particles
viral vectors
particles
Prior art date
Application number
BR112023004874A
Other languages
English (en)
Inventor
Marie Dedeurwaerdere Stefanie
Kramer Tal
Sipeky Csilla
Nicole Vallette Brittany
Xu Meiyu
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of BR112023004874A2 publication Critical patent/BR112023004874A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CONSTRUÇÕES DE ÁCIDO NUCLÉICO, VETORES VIRAIS E PARTÍCULAS VIRAIS. A presente invenção se refere a construções de ácido nucléico, vetores virais e partículas virais compreendendo um transgene que codifica GAT-1 e uso de tais partículas virais para tratar doenças mediadas por deterioração de SLC6A1.
BR112023004874A 2020-10-09 2021-10-07 Construções de ácido nucléico, vetores virais e partículas virais BR112023004874A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089817P 2020-10-09 2020-10-09
PCT/EP2021/077666 WO2022074105A1 (en) 2020-10-09 2021-10-07 Nucleic acid constructs, viral vectors and viral particles

Publications (1)

Publication Number Publication Date
BR112023004874A2 true BR112023004874A2 (pt) 2023-05-02

Family

ID=78332750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004874A BR112023004874A2 (pt) 2020-10-09 2021-10-07 Construções de ácido nucléico, vetores virais e partículas virais

Country Status (18)

Country Link
US (1) US20230365652A1 (pt)
EP (1) EP4225782A1 (pt)
JP (1) JP2023544264A (pt)
KR (1) KR20230083335A (pt)
CN (1) CN116390935A (pt)
AR (1) AR123756A1 (pt)
AU (1) AU2021358413A1 (pt)
BR (1) BR112023004874A2 (pt)
CA (1) CA3195052A1 (pt)
CL (1) CL2023000785A1 (pt)
CO (1) CO2023002727A2 (pt)
EC (1) ECSP23024245A (pt)
IL (1) IL301255A (pt)
MX (1) MX2023003994A (pt)
PE (1) PE20230987A1 (pt)
TW (1) TW202229321A (pt)
WO (1) WO2022074105A1 (pt)
ZA (1) ZA202304290B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110607WA (en) 2019-04-01 2021-10-28 Tenaya Therapeutics Inc Adeno-associated virus with engineered capsid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US6225115B1 (en) * 1992-03-04 2001-05-01 Synaptic Pharmaceutical Corporation DNA encoding taurine and GABA transporters and uses thereof
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
EP1859060A2 (en) * 2005-02-28 2007-11-28 Integragen Human autism susceptibility genes encoding a neurotransmitter transporter and uses thereof
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
US20220127373A1 (en) * 2018-11-08 2022-04-28 The Regents Of The University Of California Systems and methods for targeting cancer cells
WO2021092518A1 (en) * 2019-11-08 2021-05-14 The Board Of Regents Of The University Of Texas Transgene cassettes, aav vectors and aav viral vectors for the expression of human codon-optimized slc6a1

Also Published As

Publication number Publication date
ECSP23024245A (es) 2023-05-31
CN116390935A (zh) 2023-07-04
KR20230083335A (ko) 2023-06-09
WO2022074105A1 (en) 2022-04-14
CL2023000785A1 (es) 2023-10-13
CA3195052A1 (en) 2022-04-14
MX2023003994A (es) 2023-04-24
EP4225782A1 (en) 2023-08-16
IL301255A (en) 2023-05-01
AU2021358413A1 (en) 2023-05-25
US20230365652A1 (en) 2023-11-16
ZA202304290B (en) 2024-09-25
PE20230987A1 (es) 2023-06-21
CO2023002727A2 (es) 2023-03-27
JP2023544264A (ja) 2023-10-23
AR123756A1 (es) 2023-01-11
TW202229321A (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
CL2018000587A1 (es) Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
CL2018002825A1 (es) Vacuna contra vrs
CL2024000411A1 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
UY38003A (es) Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
CO2019014840A2 (es) Vectores aav auto reguladores para la expresion segura de mecp2 en sidrome de rett
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
CO2021006362A2 (es) Construcciones de ácido nucleico y métodos de uso
UY38503A (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos
MX2019006722A (es) Construcciones de adenovirus de chimpance con antigenos de lyssavirus.
CL2018000164A1 (es) Vector recombinante del virus orf.
BR112022001912A2 (pt) Composições celulares compreendendo vetores virais e métodos de tratamento
ECSP23024245A (es) Construcciones de ácido nucleico, vectores virales y partículas virales
EA201691981A1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение
MX366836B (es) Celulas aviares para la produccion mejorada de virus.
MX2021001292A (es) Metodos para la modificacion genica de celulas hematopoyeticas.
CO2021009271A2 (es) Rhabdovirus recombinante que codifica ccl21
CL2022000539A1 (es) Composiciones y métodos para inhibir la expresión del gen lect2
UY37448A (es) Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
AR115379A1 (es) Ácido nucleico para tratar alergia a los ácaros
EA201991797A1 (ru) Высокоактивный и короткий промотор, предназначенный для экспрессии гетерологичных генов
EA202191065A1 (ru) Конструкции нуклеиновых кислот и способы их применения
CO2024005920A2 (es) Constructos de ácido nucleico, vectores víricos y partículas víricas
MX2020013284A (es) Vacuna basada en particulas virales.